The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
about
Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesStructural definition of a conserved neutralization epitope on HIV-1 gp120Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designEvolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41An improved microtiter assay for evaluating anti-HIV-1 neutralizing antibodies from sera or plasmaStructure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding siteTetraspanins in viral infections: a fundamental role in viral biology?Cryptic Properties of a Cluster of Dominant Flavivirus Cross-Reactive Antigenic SitesFine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.The good and evil of complement activation in HIV-1 infectionHIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 useComplement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infectionRapid evolution of the neutralizing antibody response to HIV type 1 infectionComparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China.Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120Exploring peptide mimics for the production of antibodies against discontinuous protein epitopes.Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responsesNeutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technologyAssociation of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infectionQuintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain.During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein.Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropismVirus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1.Feline immunodeficiency virus-infected cat sera associated with the development of broad neutralization resistance in vivo drive similar reversions in vitro.Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus.Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivityInduction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.
P2860
Q24538755-B64CB532-7D8F-4D1F-B34A-0A0C4B66ED0BQ24561905-428BA9E1-507B-4620-A569-F6A84B8F2D8FQ24655948-2EC2B089-538D-4893-93FB-5FD36AAF9CF6Q24679395-DCA5B8BB-13EC-4576-AA67-D950E820C652Q24802514-EA675BB3-B442-4363-93EE-54E1F1D685C3Q24807239-C98A3236-C5F5-4639-AEAC-D406540EAF87Q27316899-B0093152-AD64-4B35-9092-257D23BB7382Q27470936-6D68ADEE-7E2C-4DE3-94C9-8AC3729253F8Q27477542-EC5662C5-027F-440D-B084-3CD57C7C3B86Q28217208-0FD35A60-8800-4ACA-8044-FA2559FC1312Q28275986-13FCB233-0E6C-4043-A9F8-64B00C20824BQ28344746-F97A126E-7FCC-4E23-B015-F2A8C753DCD8Q28766705-5D090ED6-6EEC-400F-BEE4-32AF28CB697BQ29618603-409E6C49-BAFC-4B47-8238-68D89ED42D7CQ30360326-A52CD73B-574A-42C5-A2A7-A9B285EAEEF3Q30537665-66289C31-512D-4356-9AA9-BEE0C387B8BDQ30701127-C14FD3C4-C5C7-4727-BFF0-12BDFFC4FC79Q31016969-723CC8F1-19AB-4D77-9DDC-C781B6E64F65Q31143293-830110A8-60AA-4928-8B06-83F1175626C6Q33374701-40E337C5-732A-4C3D-B558-D4AAF06A3EFDQ33520582-C620FD92-7988-412A-9CD1-1E470B82618BQ33665816-BA83705A-65D9-41C2-84FD-AA4CD4172F8CQ33688229-D5E66121-B1C7-421A-A216-B8D9647E6BE7Q33813212-4710822E-A73A-4802-8A60-326567F95293Q33822395-4AECF715-A199-4928-B3C1-D6AD34F127C2Q33835324-5FE574F8-5951-46C4-9ADB-C06149363096Q33839044-CAD60605-FCCE-458B-9F31-645F94E81D98Q33840406-D894FCA5-7FE5-4F46-A4A3-CC2DD93B9B8FQ33842152-4F4493B8-476F-40BF-98D7-BEBA3E0515B5Q33842455-F8F6EADF-A998-4AEE-AB0A-469C26F6FCF4Q33843345-23140427-4F8B-47F5-A5AA-4533F248E98AQ33847697-6FF57BBE-C352-4EC3-8945-11E97C970FEBQ33854138-AF27EDD8-80F1-473F-B389-5EDAC534EEDBQ33854938-CB28114D-B9E8-4D8B-B387-EE5582EEAA16Q33870236-E525B39A-55C5-4407-B992-1BD3EE9955ABQ33883887-14633FBE-4106-466A-BFCD-019919B1C2E4Q33953062-36863F30-997F-4E0A-95C2-D89764B719BEQ33984296-DD8E2B78-D49D-44A4-BC99-61AABDBF941CQ33987391-FE978FEC-0BF7-435C-B944-CE48D2D358F0Q34142795-C3A51498-9F01-4FDE-B9A7-6155413F1251
P2860
The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The neutralizing antibody resp ...... escape from humoral immunity.
@ast
The neutralizing antibody resp ...... escape from humoral immunity.
@en
type
label
The neutralizing antibody resp ...... escape from humoral immunity.
@ast
The neutralizing antibody resp ...... escape from humoral immunity.
@en
prefLabel
The neutralizing antibody resp ...... escape from humoral immunity.
@ast
The neutralizing antibody resp ...... escape from humoral immunity.
@en
P2093
P1433
P1476
The neutralizing antibody resp ...... escape from humoral immunity.
@en
P2093
P304
P407
P478
13 Suppl A
P577
1999-01-01T00:00:00Z